Pelubiprofen

培比洛芬

Report date: 2022/09/05 15:39:34
NME

Base Information

Drug NamePelubiprofen
Drug Alias Name培鲁比洛芬Pelubiprofen sustained releasepelubiprofenumpelubiprofenoPelubi +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclooxygenases inhibitors
TargetsCyclooxygenases
Therapy Area/IndicationsWounds and InjuriesLow Back PainBack Pain +[8] 
Global Approved IndicationsBack PainOsteoarthritis
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2008/12/01
Country/TerritorySouth KoreaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDaewon Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaewon Pharmaceutical Co LtdShenyang Dashan Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLow Back PainBack PainOsteoarthritis +[4] 
Inactive IndicationsWounds and InjuriesFeverDysmenorrhea +[4] 

Other Information

ATC CodeM01AE
Related LinksKEGG